Sign in

You're signed outSign in or to get full access.

SI

SYNLOGIC, INC. (SYBX)·Q1 2024 Earnings Summary

Executive Summary

  • Q1 2024 was dominated by the February decision to discontinue Synpheny-3 (Phase 3 PKU) and initiate a strategic alternatives review; the quarter carried $28.289M in restructuring charges and an increased net loss per share of $2.60 .
  • Revenue fell to $0.008M, down sharply vs Q4 2023 ($2.769M) and YoY ($0.174M), reflecting minimal collaboration activity and the wind-down after program discontinuation .
  • Management retained Lucid Capital Markets to explore strategic options; no timetable was set and no outcome is assured, creating event-driven catalysts around potential transactions and portfolio actions .
  • No earnings call transcript was available for Q1 2024; communication came via 8-K and press releases, with clear emphasis on ceasing operations and workforce reduction (~90%) .

What Went Well and What Went Wrong

What Went Well

  • Operating expense discipline: R&D declined to $7.680M and G&A to $2.884M vs $12.450M and $3.967M in Q1 2023 as the company reduced spend and activity post-discontinuation .
  • Other income uplift: a $6.730M favorable fair value change in purchase warrant liability supported other income (expense), net of $7.281M in Q1 2024 .
  • Management transparency and decisive action: “It is with a heavy heart that we share this news, and our resulting decision to end Synpheny-3…,” reflecting candid communication and a prompt strategic review initiation .

What Went Wrong

  • Program failure: An internal review indicated Synpheny-3 was unlikely to meet the primary endpoint; the pivotal PKU program was discontinued, eliminating the near-term registrational asset .
  • Financial hit: Restructuring and other charges of $28.289M drove operating loss to $(38.845)M and widened net loss to $(31.564)M in Q1 2024 .
  • Revenue collapse: Q1 revenue declined to $0.008M, well below Q4 2023 ($2.769M) and Q1 2023 ($0.174M), underscoring limited remaining collaboration activity .

Financial Results

MetricQ1 2023Q4 2023Q1 2024
Revenue ($USD Millions)$0.174 $2.769 $0.008
Net Loss per Share ($USD)$(3.39) $(1.71) $(2.60)
Research & Development ($USD Millions)$12.450 $10.207 $7.680
General & Administrative ($USD Millions)$3.967 $3.203 $2.884
Restructuring & Other Charges ($USD Millions)— — $28.289
Loss from Operations ($USD Millions)$(16.243) $(10.641) $(38.845)
Net Loss ($USD Millions)$(15.622) $(14.533) $(31.564)

KPIs

KPIQ1 2023Q4 2023Q1 2024
Cash, Cash Equivalents & Marketable Securities ($USD Millions)$57.4 $47.7 $32.3
Total Liabilities ($USD Millions)$28.255 $32.895 $22.732
Total Stockholders’ Equity ($USD Millions)$82.610 $42.655 $13.325

Notes: Q1 2023 EPS presented in Q1 2024 statements is $(3.39) vs $(0.23) disclosed in the original Q1 2023 press release; the Q1 2024 8-K financial statements should be treated as the authoritative comparable set .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Synpheny-3 (PKU) timeline2024–2025Complete enrollment H2 2024; top-line H1 2025 Program discontinued Feb 8, 2024 Withdrawn
Cash Runway2025Into H1 2025 (post Oct financing & Roche milestone) Strategic alternatives; cease operations; no runway guidance provided Withdrawn
Operations status2024Normal operations pursuing pivotal PKU study Cease operations; ~90% workforce reduction; strategic review Lowered
Revenue guidance2024Not providedNot providedMaintained (no guidance)

Earnings Call Themes & Trends

No Q1 2024 earnings call transcript was available; themes are drawn from press releases/8-Ks.

TopicPrevious Mentions (Q3 2023, Q4 2023)Current Period (Q1 2024)Trend
R&D execution (PKU)Progress in Synpheny-3; Fast Track designation; Phase 3 timeline PKU Phase 3 discontinued after internal review Deteriorating
Regulatory statusFast Track (PKU); IP/patent updates No new regulatory milestones; strategy shift Paused/uncertain
Strategic alternativesNot a focus in Q3/Q4 updates Formal strategic review; Lucid Capital engaged New priority
Workforce/OpExStandard operations; expense control ~90% reduction; $28.289M restructuring Restructuring
Collaboration revenues (Roche)Milestone $2.5M earned; Q3 rev $0.393M Minimal rev ($0.008M; material transfer) Lower
Corporate defense (Rights Plan)Not highlightedRights Plan adopted Feb 20, 2024 (poison pill) Defensive posture

Management Commentary

  • Aoife Brennan (former CEO) on Synpheny-3 discontinuation: “It is with a heavy heart that we share this news, and our resulting decision to end Synpheny-3… we had expected the study to demonstrate the potential for SYNB1934 to provide an important new treatment option for those affected by PKU” .
  • Strategic alternatives framing: Board plans to assess options including acquisition, merger, asset sale, dissolution; no timetable and no assurance of transaction .
  • Corporate update Q1 2024: engagement of Lucid Capital Markets to explore strategic options; reiteration that outcomes and timing remain uncertain .

Q&A Highlights

  • No Q1 2024 earnings call/Q&A transcript was available; communication was via 8-K and press releases .
  • Clarifications provided in filings: decision based on internal review indicating the trial unlikely to meet primary endpoint; not based on safety/tolerability concerns .
  • Workforce reduction specifics: ~90% reduction, expected to complete substantially by end of Q1 2024; estimated ~$6M in severance/termination benefits .

Estimates Context

  • Attempted to retrieve Wall Street consensus (S&P Global Capital IQ) for Q1 2024 EPS and revenue; data was unavailable at the time due to request-limit constraints. As such, estimates comparison is not provided here, and investors should assume no SPGI consensus reference for this quarter [GetEstimates error].
  • If/when SPGI estimates become available, we would anchor comparisons to “Primary EPS Consensus Mean” and “Revenue Consensus Mean” and flag beats/misses accordingly.

Key Takeaways for Investors

  • The registrational PKU asset has been discontinued, removing the principal near-term value driver; the equity story shifts to corporate actions (M&A, asset sales) and residual value realization .
  • Q1 2024 financials reflect wind-down: revenue at $0.008M, operating loss $(38.845)M driven by $28.289M restructuring; expect lower R&D/G&A run-rate thereafter but limited operating activity .
  • Cash stood at $32.3M on March 31, 2024; with operations ceased, liquidity supports the strategic review process and/or transaction-related expenses .
  • Defensive measures adopted (Rights Plan, Feb 20, 2024) signal intent to manage potential unsolicited bids during the review; this can influence deal dynamics and timing .
  • Event-driven setup: stock likely reacts to concrete developments in the strategic alternatives process (LOIs, definitive agreements, asset sales), and any updates to balance sheet/liability resolution .
  • Near-term trading: limited fundamental catalysts; monitor SEC filings and press releases closely for transaction steps, workforce wind-down costs, and any residual collaboration inflows .
  • Medium-term thesis: focus on net cash, liabilities (including warrant-related fair value impacts), and potential recovery from asset monetization; absence of ongoing pipeline reduces operational risk but concentrates outcomes around corporate actions .

Sources: Q1 2024 8-K and press release ; Q4 2023 8-K and press release ; Q3 2023 8-K and press release ; Q1 2023 8-K and press release ; Rights Plan reference (10-Q) .